Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Other Non-Current Liabilities (2020 - 2025)

Candel Therapeutics' Other Non-Current Liabilities history spans 4 years, with the latest figure at $916000.0 for Q4 2023.

  • On a quarterly basis, Other Non-Current Liabilities fell 51.33% to $916000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $916000.0, a 51.33% decrease, with the full-year FY2023 number at $916000.0, down 51.33% from a year prior.
  • Other Non-Current Liabilities hit $916000.0 in Q4 2023 for Candel Therapeutics, up from $433000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for CADL hit a ceiling of $27.4 million in Q3 2021 and a floor of $433000.0 in Q3 2023.
  • Historically, Other Non-Current Liabilities has averaged $8.1 million across 4 years, with a median of $4.8 million in 2022.
  • Biggest five-year swings in Other Non-Current Liabilities: skyrocketed 167.19% in 2021 and later plummeted 90.64% in 2023.
  • Tracing CADL's Other Non-Current Liabilities over 4 years: stood at $6.8 million in 2020, then skyrocketed by 167.19% to $18.3 million in 2021, then crashed by 89.69% to $1.9 million in 2022, then plummeted by 51.33% to $916000.0 in 2023.
  • Business Quant data shows Other Non-Current Liabilities for CADL at $916000.0 in Q4 2023, $433000.0 in Q3 2023, and $1.0 million in Q2 2023.